Project description:<p>The Geisinger eMERGE Genome-Wide Association Studies of Obesity Project is a genetic study of a cohort of primarily Caucasian patients with extreme obesity who have undergone bariatric surgery. Roux-en-Y gastric bypass (RYGB) surgery, in which intestinal anatomy is altered, dramatically ameliorates and/or eliminates Type 2 diabetes mellitus (T2D) in 50-80% of patients within hours to days following surgery, well before significant weight loss, in contrast to other types of bariatric surgeries, such as gastric banding, that attenuate insulin resistance as a result of substantial weight loss that occurs over months to years. The molecular mechanism by which RYGB exerts this clinical phenomenon occurs is not known. The goal of this project was to conduct a genome-wide association study (GWAS) to identify genetic variants associated with amelioration in T2D defined by medication independence. Identifying genetic variants that influence the dramatic resolution of T2D from RYGB may identify novel targets for pharmacological T2D therapies and/or identify patients in whom RYGB may not be effective.</p>

| phs000408.v1.p1 | EGA

eMERGE Genome-Wide Association Studies of Obesity (Metabochip)

Project description:<p>The Geisinger eMERGE Genome Wide Association Studies of Obesity (Metabochip) Project is a genetic study of a cohort of primarily Caucasian patients with extreme obesity who have undergone bariatric surgery. Roux-en-Y gastric bypass (RYGB) surgery, in which intestinal anatomy is altered, dramatically ameliorates and/or eliminates Type 2 diabetes mellitus (T2D) in 50-80% of patients within hours to days following surgery, well before significant weight loss, in contrast to other types of bariatric surgeries, such as gastric banding, that attenuate insulin resistance as a result of substantial weight loss that occurs over months to years. The molecular mechanism by which RYGB exerts this clinical phenomenon is not known. The goal of this project was to conduct a genome wide association study (GWAS) to identify genetic variants associated with amelioration in T2D defined by medication independence. Identifying genetic variants that influence the dramatic resolution of T2D from RYGB may identify novel targets for pharmacological T2D therapies and/or identify patients in whom RYGB may not be effective.</p>

| phs000380.v1.p1 | EGA

eMERGE-I Genome Wide Association Studies of Network Phenotypes

Project description:eMERGE-I Genome Wide Association Studies of Network Phenotypes

| PRJNA75857 | ENA

eMERGE Genome Wide Association Studies of Cardiovascular Diseases and T2DM

Project description:eMERGE Genome Wide Association Studies of Cardiovascular Diseases and T2DM

| PRJNA75957 | ENA

eMERGE Genome Wide Association Study of Dementia

Project description:eMERGE Genome Wide Association Study of Dementia

| PRJNA75533 | ENA

Homo sapiens

Project description:eMERGE Genome Wide Association Studies - Controls for AAA and Obesity